James B Mitchell Selected Research

tempol

1/2022	The antioxidant tempol transforms gut microbiome to resist obesity in female C3H mice fed a high fat diet.
1/2019	Effects of oxygen challenging to tissue redox and pO2 status.
5/2017	Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models.
8/2015	Selective enhancement of hypoxic cell killing by tempol-regulated suicide gene expression.
5/2015	The nitroxide radical TEMPOL prevents obesity, hyperlipidaemia, elevation of inflammatory cytokines, and modulates atherosclerotic plaque composition in apoE-/- mice.
10/2014	Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol.
7/2014	DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer.
1/2013	Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity.
12/2012	The relationship between tissue oxygenation and redox status using magnetic resonance imaging.
11/2012	Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James B Mitchell Research Topics

Disease

103	Neoplasms (Cancer) 01/2022 - 01/2002
21	Hypoxia (Hypoxemia) 10/2021 - 02/2002
15	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2018 - 02/2002
9	Inflammation (Inflammations) 01/2022 - 03/2002
8	Fibrosis (Cirrhosis) 11/2016 - 05/2007
7	Squamous Cell Carcinoma of Head and Neck 01/2021 - 12/2005
7	Head and Neck Neoplasms (Head and Neck Cancer) 01/2016 - 03/2004
7	Radiation Fibrosis Syndrome (Radiation Fibrosis) 09/2014 - 03/2002
7	Carcinogenesis 08/2013 - 01/2003
6	Carcinoma (Carcinomatosis) 06/2022 - 12/2003
5	Adenocarcinoma 01/2022 - 11/2002
5	Breast Neoplasms (Breast Cancer) 07/2014 - 11/2002
4	Obesity 01/2022 - 08/2010
4	Colonic Neoplasms (Colon Cancer) 01/2021 - 02/2010
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 11/2002
3	Weight Gain 01/2022 - 08/2004
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 06/2003
3	Renal Cell Carcinoma (Grawitz Tumor) 12/2019 - 06/2003
3	Stroke (Strokes) 01/2019 - 02/2003
3	Xerostomia 01/2016 - 10/2005
3	Stomatitis 04/2013 - 07/2009
3	Body Weight (Weight, Body) 09/2012 - 10/2009
3	Radiation Injuries (Radiation Sickness) 11/2010 - 06/2003
2	Necrosis 01/2021 - 01/2018
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 09/2012
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 11/2016 - 04/2016
2	Weight Loss (Weight Reduction) 01/2016 - 08/2010
2	Kidney Neoplasms (Kidney Cancer) 12/2014 - 11/2012
2	Brain Neoplasms (Brain Tumor) 07/2014 - 06/2003
2	Contracture 03/2013 - 08/2009
2	Lymphoma (Lymphomas) 09/2012 - 08/2004
2	Ulcer 07/2012 - 07/2005
2	Lung Neoplasms (Lung Cancer) 02/2012 - 06/2003

Drug/Important Bio-Agent (IBA)

30	Oxygen (Dioxygen)IBA 03/2021 - 02/2002
24	tempolIBA 01/2022 - 01/2003
19	nitroxylIBA 06/2022 - 05/2002
14	AntioxidantsIBA 01/2022 - 01/2003
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2003
12	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2009
12	Pyruvic Acid (Pyruvate)IBA 01/2021 - 02/2011
9	Lactic Acid (Lactate)FDA LinkGeneric 11/2020 - 05/2008
9	Contrast MediaIBA 02/2018 - 02/2002
9	CytokinesIBA 10/2017 - 12/2005
8	carbogenIBA 08/2010 - 02/2002
7	ProdrugsIBA 10/2021 - 09/2005
7	Pharmaceutical PreparationsIBA 10/2021 - 12/2003
7	Transforming Growth Factor beta (TGF-beta)IBA 03/2010 - 03/2002
5	TH 302IBA 10/2021 - 01/2014
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 06/2008
5	Biological ProductsIBA 10/2017 - 06/2003
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 11/2020 - 11/2015
4	EnzymesIBA 12/2019 - 07/2004
4	Sunitinib (Sutent)FDA Link 09/2014 - 10/2009
4	Messenger RNA (mRNA)IBA 08/2013 - 06/2003
3	pimonidazoleIBA 10/2021 - 04/2007
3	FumaratesIBA 01/2021 - 12/2014
3	Cytidine Monophosphate (CMP)IBA 01/2019 - 01/2011
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2011
3	Protons (Proton)IBA 01/2018 - 02/2002
3	Oxo63IBA 01/2018 - 02/2002
3	TOR Serine-Threonine KinasesIBA 11/2016 - 01/2012
3	Small Interfering RNA (siRNA)IBA 01/2016 - 08/2013
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2015 - 04/2003
3	Free RadicalsIBA 10/2014 - 07/2003
3	Complementary DNA (cDNA)IBA 07/2014 - 04/2007
3	Transforming Growth Factors (Transforming Growth Factor)IBA 08/2013 - 12/2003
3	Transcription Factors (Transcription Factor)IBA 08/2013 - 09/2004
3	IronIBA 01/2011 - 07/2002
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 08/2013
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 06/2010
2	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2018
2	malic acid (malate)IBA 01/2021 - 01/2018
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 02/2006
2	Fumarate Hydratase (Fumarase)IBA 12/2019 - 12/2014
2	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2019 - 12/2005
2	ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA 12/2018 - 10/2009
2	NitroimidazolesIBA 01/2018 - 04/2007
2	isophosphamide mustard (IPAM)IBA 01/2018 - 01/2014
2	Gemcitabine FDA Link 01/2018 - 11/2002
2	Amifostine (Ethyol)FDA LinkGeneric 01/2018 - 05/2017
2	Sirolimus (Rapamycin)FDA Link 11/2016 - 01/2012
2	Hydroxyproline (4 Hydroxyproline)IBA 11/2016 - 04/2016
2	Coloring Agents (Dyes)IBA 08/2015 - 09/2014
2	Tyrosine Kinase InhibitorsIBA 09/2014 - 10/2011
2	Angiogenesis InhibitorsIBA 09/2014 - 10/2011
2	Phosphotransferases (Kinase)IBA 08/2013 - 04/2010
2	Cisplatin (Platino)FDA LinkGeneric 08/2013 - 07/2012
2	pifithrinIBA 08/2013 - 07/2013
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 08/2013 - 12/2003
2	TEMPOIBA 02/2012 - 03/2005
2	Ferritins (Ferritin)IBA 01/2011 - 08/2008

Therapy/Procedure

39	Radiotherapy 06/2022 - 11/2002
24	Therapeutics 10/2021 - 01/2002
10	Drug Therapy (Chemotherapy) 10/2021 - 11/2002
4	Aftercare (After-Treatment) 07/2014 - 11/2002
2	Immunotherapy 01/2019 - 01/2017
2	Intravenous Injections 12/2018 - 02/2011
2	Anesthesia 01/2018 - 03/2008
2	Injections 07/2014 - 02/2006
2	Intravenous Administration 01/2014 - 03/2012